Amneal (AMRX) files Form 144 for 32,000 equity-comp shares

Rhea-AI Filing Summary

Amneal Pharmaceuticals (AMRX) filed a Form 144 to notify a proposed sale of 32,000 Class A shares through Merrill Lynch (157 Church St, New Haven, CT) with an approximate sale date of 08/27/2025. The filing reports an aggregate market value of $293,810 for the shares and shows 314,079,309 shares outstanding for the class. The shares were acquired on 05/10/2024 as equity compensation from Amneal Pharmaceuticals, with payment recorded on the same date. The filer reports no sales in the past three months and provides the standard certification that no undisclosed material adverse information is known.

Positive

• Complete disclosure of broker, share count, aggregate value, acquisition date and nature (equity compensation).
• No sales in the past three months reported, which reduces Rule 144 aggregation concerns.

Negative

• None.

Insights

Securities Compliance Analyst

TL;DR: Standard Form 144 notice for a scheduled sale of equity compensation; timing, broker and amounts are disclosed.

The filing is procedural and contains the information required under Rule 144: class of security, broker, number of shares, aggregate market value, outstanding shares, acquisition date and nature (equity compensation), and intended sale date. The absence of sales in the prior three months simplifies aggregation considerations. From a compliance perspective, the filing appears complete for the disclosed transaction; it includes the filer’s representation regarding material non-public information.

Equity Issuance Specialist

TL;DR: This is an internal equity-compensation sale notice rather than an open-market dilution event.

The shares originated from equity compensation awarded on 05/10/2024 and the intended sale (32,000 shares) represents a small fraction of the reported 314,079,309 outstanding Class A shares (approximately 0.0102%). The disclosure of broker and aggregate value ($293,810) provides market context for the planned disposal. No prior 3-month sales are listed, reducing immediate rule 144 aggregation complexity. The filing is routine and informational.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
CLASS A	MERRILL LYNCH 157 CHURCH ST, FL 26 NEW HAVEN CT 06510	32000	293810.00	314079309	08/27/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
CLASS A	05/10/2024	EQUITY COMPENSATION	AMNEAL PHARMACEUTICALS			32000	05/10/2024	EQUITY COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed by Amneal Pharmaceuticals (AMRX) disclose?

The Form 144 discloses an intended sale of 32,000 Class A shares through Merrill Lynch on or about 08/27/2025, with an aggregate market value of $293,810.

When and how were the shares being sold acquired?

The 32,000 shares were acquired on 05/10/2024 as equity compensation from Amneal Pharmaceuticals.

How many Class A shares are outstanding according to the filing?

The filing reports 314,079,309 Class A shares outstanding.

Did the filer report any sales of issuer securities in the past three months?

No. The filing states Nothing to Report for securities sold during the past three months.

Who is the broker listed for the proposed sale?

The broker named is Merrill Lynch with address listed as 157 Church St, Fl 26, New Haven, CT 06510.